Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL Q365_E366insSK FLT3 pos||hematologic cancer||sensitive||PRT062607 + Quizartinib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of PRT062607 to treatment with Quizartinib (AC220) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).||31943762|